159 One-year experience of routine electronic patient-reported outcome measures (ePROMs) in patients undergoing chemoradiotherapy for glioblastoma

Abstract Introduction Symptom assessment and quality-of-life (QOL) evaluation are central to cancer care, particularly for patients with glioblastoma (GBM), who frequently experience neurological and treatment-related morbidity during chemoradiotherapy (CRT). Electronic patient-reported outcome measures (ePROMs) enable systematic symptom capture in routine practice. We describe feasibility, symptom burden, and QOL outcomes captured using a neuro-oncology-specific ePROM before and after CRT for GBM. Method ePROMs are integrated into routine neuro-oncology practice at our centre. Questionnaires are issued electronically three days before clinic visits, and include EQ-5D-5L and 25 CTCAE-adapted symptom items. We analysed patients undergoing radical CRT with temozolomide, including ePROM submissions completed within four weeks before and after CRT. Results Between October 2024 and October 2025, 29 patients receiving six weeks CRT were offered ePROMs. 23 (79%) submitted at least one. Twenty-one contributed pre-CRT data, 11 post-CRT data, nine (31%) completed both timepoints. Median age: 61 years (IQR: 55 – 67); 12 (41%) female, 26 (90%) ECOG 0-1. Pre-CRT (n = 21), fatigue (19/21, 90%), insomnia (12/21, 57%), and memory concerns (10/21, 48%) were most frequent. Post-CRT (n = 11), fatigue (9/11, 82%) and memory concerns (6/11, 55%) remained common, while insomnia was less frequent (4/11, 36%). Other symptoms were reported by fewer than 50% of patients at both timepoints and were generally mild (grade 1). Regarding QOL, pre-CRT, 12/21 (57%) reported usual activity limitations and 6/21 (29%) anxiety/depression; post-CRT, 4/11 (36%) and 4/11 (36%), respectively. Median overall health score:70 (IQR 50-80) pre-CRT and 80 (IQR 75-90) post-CRT. Conclusions Routine ePROM collection is feasible within standard neuro-oncology practice and provides descriptive insight into patient-reported symptoms during CRT. Larger prospective studies are needed to assess associations with clinical outcomes and better understand response patterns and potential selection bias.